Recent Publications

248. Zaugg, A., Sherren, E., Yi, R., Larsen, T., Dyck, B., Stump, S., Pauga, F., Linder, A., Takara, M., Gardner, E., Shin, S., Pulsipher, J., & Savage, P. B. (2023). Incorporating ceragenins into coatings protects peripherally inserted central catheter lines against pathogen colonization for multiple weeks. International Journal of Molecular Sciences, 24(19), 14923. https://doi.org/10.3390/ijms241914923

247. Wnorowska, U.; Piktel, E.; Duptula, P.; Wollny, T.; Krol, G.; Gluszek, K.; Durnas, B.; Pogoda, K; Savage, P. B.; Bucki, R. Sci. Reports 2022, 12, 19164. Ceragenin CSA‐13 displays high antibacterial efficiency in a mouse model of urinary tract infection.

246. Dao, A.; McDonald, M. M.; Savage, P. B.; Little, D. G.; Schindeler, A. J. Bone Oncol. 2022, 37, 100460. Preventing osteolytic lesions and osteomyelitis in multiple myeloma.

245. Oyardi, O.; Savage, P. B.; Guzel, C. B. Pathogens 2022, 11, 1044. Effects of ceragenins and antimicrobial peptides on the A549 cell line and in vitro co-culture model of A549 cells and Pseudomonas aeruginosa.

244. Paprocka, P.; Mankowska, A.; Sklodowski, K.; Krol, G.; Wollny, T.; Lesaik, A.; Gluszek, K.; Savage, P. B.; Durnas, B.; Bucki, R. Pathogens 2022, 11, 621. Bactericidal activity of ceragenin in combination with ceftazidime, levofloxacin, co-trimoxazole, and colistin against the opportunistic pathogen Stenotrophomonas maltophilia.

243. Tokujuk, J.; Deptula, P.; Chmielewska, S. J.; Sklodowski, K.; Mierzejewska, Z. A.; Gradzka-Dahlke, M; Tolstoj, A.; Daniluk, T.; Paprocka, P.; Savage, P. B.; Bucki, R. Pathogens 2022, 11, 491. Ceragenin CSA-44 as a means to control the formation of the biofilm on the surface of tooth and composite fillings.

242. Demir, E. S.; Oyardi, O.; Savage, P. B.; Altay, H. O.; Bozkurt-Guzel, C. J. Antibiot. 2022, 75, 403-409. In vitro activity of ceragenins against Burkholderia cepacia complex

241. Mitchell, G.; Silvis, M. R.; Talkington, K. C.; Budzik, J. M.; Dodd, C. E.; Paluba, J. M.; Oki, E. A.; Trotta, K. L.; Licht, D. J.; Jimenez-Morales, D.; Chou, S.; Savage, P. B.; Gross, C. A.; Marletta, M. A.; Cox, J. S. mBio 2022, 13, e02726. Ceragenins and antimicrobial peptides kill bacteria through distinct mechanisms.

240. Paprocka, P. Durnas, B.; Mankowska, A.; Sklodowski, K.; Krol, G.; Zakrzewska, M.; Czarnowski, M.; Kot, P.; Fortunka, K.; Gozdz, S.; Savage, P. B.; Bucki, R. Infect. Drug Resist. 2021, 14, 5681-5698. New b-lactam antibiotics and ceragenins - A study to assess their potential in treatment of infections caused by multidrug-resistant strains of Pseudomonas aeruginosa.

239. Prasad, S. V.; Piktel, E.; Depcuich, J.; Maximenko, A.; Suprewicz, L.; Daniluk, T.; Spalek, J.; Wnorowska, U.; Zielinski, P. M.; Parlinska-Wojtan, M.; Savage, P. B.; Olka, S.; Fiedoruk, K.; Bucki, R. Nanomedicine 2021, 16, 2657-2678. Targeting bacteria causing otitis media using nanosystems containing nonsperical gold nanoparticles and ceragenins.

238. Skłodowski, K.; Chmielewska, S. J.; Depciuch, J.; Deptuła, P.; Piktel, E.; Daniluk, T.; Zakrzewska, M.; Czarnowski, M.; Cieśluk, M.; Durnaś, B.; Parlinska-Wojtan, M.; Savage, P. B.; Bucki, R. Pharmaceutics 2021, 13, 1940. Ceragenin-coated non-spherical gold nanoparticles as novel candidacidal agents.

237. Piktel, E.; Ościłowska, I.; Łukasz Suprewicz, Ł.; Depciuch, J.; Marcińczyk, N.; Chabielska, E.; Wolak, P.; Głuszek, K.; Klimek, J.; Zieliński, P. M.; Marzec, M. T.; Savage, P. B.; Parlińska-Wojtan, M.; Bucki, R. Cancers, 2021, 13, 5424. Peanut-shaped gold nanoparticles with shell of ceragenin CSA-131 display ability to inhibit ovarian cancer growth in vitro and in a tumor xenograft model.

236. Spałek, J.; Daniluk, T.; Godlewski, A.; Deptuła, P.; Wnorowska, U.; Ziembicka, D.; Cieśluk, M.; Fiedoruk, K.; Ciborowski, M.; Krętowski, A.; Góźdź, S.; Durnaś, B.; Savage, P. B.; Okła, S.; Bucki, R. Pathogens 2021, 10, 1371. Assessment of ceragenins in prevention of damage to voice prostheses caused by Candida biofilm formation.

235. Kamble, S.; Valtchev, P.; Dao, A.; Pelras, T.; Rogers, M. J.; Savage, P. B.; Dehghani, F.; Schindeler, A. Molecules 2021, 26, 1541. Synthesis and characterization of bone binding antibiotic-1 (BBA-1), a novel antimicrobial for orthopedic applications.

234. Chmielewska, S. J.; Sklodoski, K; Depciuch, J.; Deptula, P.; Piktel, E.; Fiedoruk, K, Kot, P.; Paprocka, P.; Fortunka, K.; Wollny, T.; Wolak, P.; Parlinska-Wojtan, M.; Savage, P. B.; Bucki, R. Pharmaceutics 2021, 13, 425. Bactericidal properties of rod-, peanut-, and star-shaped gold nanoparticles coated with ceragenin CSA-131 against multidrug-resistant bacterial strains.

233. Haynie, T.; Gubler, S.; Drees, C.; Heaton, T.; Mitton, T.; Gleave, Q.; Bendelac, A.; Deng, S.; Savage, P. B. RCS Advances 2021, 11, 14357-14361. Synthesis of the pentasaccharide repeating unit from Ruminococcus gnavus and measurement of its inflammatory properties.

232. Kirshbaum, C.; Greis, K.; Mucha, E.; Kain, S.; Deng, S.; Zappe, A.; Gewinner, S.; Schöllkopf W.; von Helden, G.; Meijer, G.; Savage, P. B.; Marianski, M.; Teyton, L.; Pagel, K. Nat. Comm. 2021, 12, 1201. Unravelling the structural complexity of glycolipids with cryogenic infrared spectroscopy.

231. Latorre, M. C.; Pérez-Granda, M. J.; Savage, P. G.; Alonso, B.; Martín-Rabadán, P.; Samaniego, R.; Bauzo, E.; Muñoz, P.; Guembe, M. J. Antimicrob. Chemother. 2021, 76, 1168-1173. Endotracheal tubes coated with a broad-spectrum antibacterial ceragenin reduce bacterial biofilm in an in vitro bench top model.

230. Oyardi, Ö, Savage, P. B.; Erturan, Z.; Bozkurt-Guzel, C. J. Antimicrob. Chemother. 2021, 76, 443-450. In vitro assessment of CSA-131 and CSA-131 poloxamer form for the treatment of Stenotrophomonas maltophilia infections in cystic fibrosis.

229. Choi, J.; Mele, T. S.; Porcelli, S. A.; Savage, P. B.; Haeryfar, S. M. M. J. Immunol. 2021, 206, 386-397. Harnessing the versatility of iNKT cells in a step-wise approach to sepsis immunotherapy.

228. Chmielewska, S. J.; Sklodowski, D.; Piktel, E.; Suprewicz, L.; Fiedoruk, K.; Daniluk, T.; Wolak, P.; Savage, P. B.; Bucki, R. Infect. Drug Resist. 2020, 13, 3277-3294. NDM-1 carbapenemase-producing Enterobacteriaceae are highly susceptible to ceragenins CSA-13, CSA-44, and CSA-131.

227. Damar-Celik, D.; Mataraci-Kara, E.; Savage, P. B.; Ozbek-Celik, B. J. Chemother. 2020, doi.org/10.1080/1120009X.2020.1819702. Antibacterial and antibiofilm activities of ceragenins against Achromobacter species isolated from cystic fibrosis patients.

226. Iweala, O. I.; Choudhary, S. K.; Addison, C. T.; Batty, C. J.; Kapita, C. M.; Amelio, C.; Schuyler, A.; Deng, S.; Bachelder, E. M.; Ainslei, K. M.; Savage, P. B.; Brennan, P. J.; Commins, S. P. J. Allergy Clin Immunol. 2020, 146, 450-452. Glycolipid-mediated basophil activation in alpha-gal allergy.

225. Piktel, E.; Markiewicz, K. H; Wilczewska, A. Z.; Daniluk, T.; Chmielewska, S.; Niemorowicz-Laskowska, K.; Mystkowska, J.; Paprocka, P.; Savage, P. B.; Bucki R. Int. J. Nanomed. 2020, 15, 4573-4589. Quantification of synergistic effects of ceragenin CSA-131 combined with iron oxide magnetic nanoparticles against cancer cells.

224. Bozkurt Guzel, C.; Avci, N. M.; Savage, P. B. Turkish J. Pharma. Sci. 2020, 17, 63-67. In vitro activities of the cationic steroid antibiotics CSA-13, CSA-131, CSA-138, CSA-142, and CSA-192 against carbapenem-resistant Pseudomonas aeruginosa.

223. Alehashem, M. S.; Bin Ariffin, A.; Savage, P. B.; Dabdawb, W. A. Y.; Thomas, N. F. RSC Adv. 2020, 10, 10989-11012. Treasures old and new: what we can learn regarding the macrocyclic problem from past and present efforts in natural product total synthesis.

222. Bozkurt-Guzel, C.; Inci, G.; Oyardi, O.; Savage, P. B. Curr. Microbiol. 2020, 77, 1419-1428. Synergistic activity of ceragenins against carbapenem-resistant Acinetobacter baumannii strains in both checkerboard and dynamic time-kill assays.

221. Hacioglu, M; Oyardi, O.; Bozkurt-Guzel, C.; Savage, P. B. J. Antibiotics 2020, 73, 455-462. Antibiofilm activities of ceragenins and antimicrobial peptides against fungal-bacterial mono and multispecies biofilms.

220. Mills, R. J.; Boyling, A.; Cheng, T. L.; Peacock, L.; Savage, P. B.; Tagin, M.; Little, D. G.; Schindeler, A. J. Orthopaedic Res. 2020, 38, 2065-2073. CSA-90 reduces periprosthetic joint infection in a novel rat model challenged with local and systemic Staphylococcus aureus.

219. Dao, A.; Mills, R. J.; Kamble, S.; Savage, P. B.; Little, D. G.; Schindeler, A. J. Orthopaedic Res. 2020, 38, 1883-1894. The application of ceragenins to orthopedic surgery and medicine.

218. Iweala, O. I.; Choudhary, S. K.; Addison, C. T.; Batty, C. J.; Kapita, C. M; Amelio, C. I.; Schuyler, A. J.; Deng, S.; Bachelder, E. M.; Ainslie, K. M.; Savage, P. B.; Brennan, P. J.; Commins, S. P. J. Allergy Clin. Immunol. 2020, 146, 450-452. Glycolipid-mediated basophil activation in alpha-gal allergy.

217. Wnorowska, U.; Fiedoruk, K.; Piktel, E.; Prasad, S. V.; Sulik, M.; Janion, M; Daniluk, T.; Savage, P. B.; Bucki, R. J. Nanobiotech. 2020, 18, 3. Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: current status and potential future applications.

Issued US Patents

54. Savage, P. B. “Methods for treating inflammation, autoimmune disorders and pain.” US Patent #11,524,015. December 13, 2022.

53. Savage, P. B. “Cationic steroidal antimicrobials.” US Patent #11,286,276. March 29, 2022.

52. Savage, P. B.; Genberg, C.; Bracken, R. “Cationic steroidal antibiotic compositions for the treatment of dermal tissue.” US Patent #11,253,634. February 22, 2022.

51. Savage, P. B. “Use of cationic steroidal antimicrobials for sporicidal activity.” US Patent #10,959,433. March 30, 2021.

50. Savage, P. B. “Hydrogel materials incorporating eluting ceragenin compound.” US Patent #10,676,501. June 9, 2020.

49. Savage, P. B. “Cationic steroid antimicrobial compounds.” US Patent #10,626,139. April 21, 2020.

48. Savage, P. B.; Genberg, C. “Methods for treating inflammation, autoimmune disorders and pain.” US Patent #10,568,893. February 25, 2020.

47. Genberg, C.; Beus, C. S.; Savage, P. B. “Methods for treating fungal infections.” US Patent #10,441,595. October 15, 2019.

46. Savage, P. B.; Jacks, T. E.; Miller, R. A.; Thompson, A. S.; Randall, J. L. “Methods for the synthesis of ceragenins.” US Patent #10,370,403. August 6, 2019.

45. Genberg, C.; Beus, C. S.; Savage, P. B. “Methods for treating fungal infections.” US Patent #10,238,665. March 26, 2019.

44. Savage, P. B. “Radiolabeled cationic steroid antimicrobials and diagnostic methods.” US Patent #10,227,376. March 12, 2019.

43. Savage, P. B.; Genberg, C.; Bracken, R. “Cationic steroidal antimicrobial compositions for the treatment of dermal tissue.” US Patent #10,226,550. March 12, 2019.

42. Genberg, C.; Savage, P. B. “Methods for cellular proliferation and treating certain diseases.” US Patent #10,195,215. February 5, 2019.

41. Savage, P. B. “Cationic steroidal antimicrobial prodrug compositions and uses thereof.” US Patent #10,155,788. December 18, 2018.

40. Savage, P. B.; Genberg, C. “Ceragenin particulate materials and methods for making same.” US Patent #10,039,285. August 7, 2018.

39. Savage, P. B. “Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods.” US Patent #9,943,614. April 17, 2018.

38. Genberg, C.; Savage, P. B. “Methods for reducing cellular proliferation and treating certain diseases.” US Patent #9,943,529. April 17, 2018.

37. Savage, P. B.; Genberg, C. “Anti-infective and osteogenic compositions and methods of use.” US Patent #9,931,350. April 3, 2018.

36. Beus, C.; Savage, P B. “Lavage and/or infusion using CSA compounds for increasing fertility in a mammal.” US Patent # 9,867,836. January 16, 2018.

35. Genberg, C.; Savage, P. B. “Compositions and methods for treating bone diseases and broken bones.” US Patent # 9,694,019. July 4, 2017.

34. Beus, C. S.; Savage, P. B. “Methods and apparatus for cleaning or disinfecting a water delivery system.” US Patent # 9,686,966. June 27, 2017.

33. Savage, P. B. “Methods and products for incresing the rate of healing of tissue wounds.” US Patent # 9,603,859. March 28, 2017.

32. Savage P. B. “Hydrophobic ceragenin compounds and devices incorporating same.” US Patent # 9,546,195. January 17, 2017.

31. Savage, P. B. “Aerosols containing ceragenins compounds and methods of use thereof.” US Patent # 9,533,063. January 3, 2017.

30. Savage, P. B.; Randall, J. L. “Methods for the synthesis of ceragenins.” US Patent # 9,527,883. December 27, 2016.

29. Savage, P. B. “Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds,” US Patent # 9,434,759. September 6, 2016.

28. Beus, C. S.; Savage, P. B. “Animal feed including cationic cholesterol additive and related methods,” US Patent # 9,387,215. July 12, 2016.

27. Beus, C. S.; Savage, P. B. “Treatment and prevention of mastitis,” US Patent # 9,314,472. April 19, 2016.

26. Savage, P. B.; Bendelac, A.; Teyton, L. “Bacterial glycolipid activation of CD1d-restricted NKT cells,” US Patent # 9,295,722. March 29, 2016.

25. Genberg, C.; Savage, P. B. “Methods and products for increasing the rate of healing of tissue wounds,” US Patent # 9,161,942. October 20, 2015.

24. Genberg, C.; Savage, P. B. “Compositions and methods for treating bone diseases and broken bones,” US Patent # 9,115,746. October 13, 2015.

23. Savage, P. B.; Bendelac, A.; Teyton, L. “6”-Amino-6”-deoxygalactosylceramides,” US Patent # 9,045,512. June 2, 2015.

22. Savage, P. B. “Hydrophobic ceragenin compounds and devices incorporating same,” US Patent # 8,975,310. March 10, 2015.

21. Savage, P. B.; Bloebaum, R. D.; Williams, D. L.; Sinclair, K. D.; Haymond, B. S. “Medical devices incorporating ceragenin-containing composites,” US Patent # 8,945,217. February 3, 2015.

20. Savage, P. B.; Genberg, C. “Incorporation of particulate ceragenins in polymers,” US Patent # 8,932,614. January 13, 2015.

19. Teyton, L.; Bendelac, A.; Savage, P. B. “Adjuvants and methods of use,” US Patent # 8,932,594. January 13, 2015.

18. Savage, P. B. “Articles incorporating absorbent polymer and ceragenin compound,” US Patent # 8,784,857. July 22, 2014.

17. Savage, P. B.; Teyton, L.; Bendelac, A. “Modified-galactosyl ceramides for staining and stimulating natural killer T cells,” US Patent # 8,765,692. July 1, 2014.

16. Savage, P. B. “Storage-stable, anti-microbial compositions including ceragenin compounds and methods of use,” US Patent # 8,691,252. April 8, 2014.

15. Hibbs, M.; Altman, S. J.; Jones, H. D. T.; Savage, P. B. “Methods for attaching polymerizable ceragenins to water treatment membranes using amine and amide linkages,” US Patent # 8,557,031. October 15, 2013.

14. Hibbs, M.; Altman, S. J.; Jones, H. D. T.; Savage, P. B. “Methods for attaching polymerizable ceragenins to water treatment membranes using silane linkages,” US Patent # 8,530,002. September 10, 2013.

13. Hibbs, M.; Altman, S. J.; Jones, H. D. T.; Savage, P. B. “Biofouling-resistant ceragenin-modified materials and structures for water treatment,” US Patent # 8,529,681. September 10, 2013.

12. Savage, P. B.; Bendelac, A.; Teyton, L. “Method of stimulating NKT with 6''-amino-6''-deoxygalactosylceramides,” US Patent # 8,445,272. May 21, 2013.

11. Teyton, L.; Bendelac, A.; Savage, P. B. “Modified -galactosylceramides for staining and stimulating NKT cells,” US Patent # 8,227,581. July 24, 2012.

10. Savage, P. B.; Leung, D. L. “Cationic Steroid Antimicrobial Compositions and Methods of Use,” US Patent # 8,211,879. July 3, 2012.

9. Bendelac, A.; Zhou, D.; Teyton, L.; Savage, P. B. “Methods of Activating NKT Cells,” US Patent # 7,998,739. August 16, 2011.

8. Savage, P. B.; Bendelac, A.; Teyton, L. “6''-amino-6''-deoxygalactosylceramides,” US Patent # 7,989,432. August 2, 2011.

7. Teyton, L.; Bendelac, A.; Savage, P. B. “Adjuvants and Methods of Use,” US Patent # 7,794,722. September 14, 2010.

6. Savage, P. B.; Leung, D. L. “Cationic Steroid Antimicrobial Compositions and Methods of Use,” US Patent # 7,754,705. July 13, 2010.

5. Savage, P. B.; Bendelac, A.; Teyton, L. “6”-Amino-6”-Deoxygalactosylceramides,” US Patent # 7,645,873. January 12, 2010.

4. Savage, P. B.; Li, C. “Steroid Derived Antibiotics,” US patent # 7,598,234. October 6, 2009.

3. Savage, P. B.; Li, C. “Steroid Derived Antibiotics,” US patent # 6,767,904. July 27, 2004.

2. Savage, P. B.; Li, C. “Steroid Derived Antibiotics,” US patent # 6,486,148. November 26, 2002.

1. Savage, P. B.; Li, C. “Steroid Derived Antibiotics,” US patent # 6,350,738. February 26, 2002.